Loading quotes...

Forecast

The analysts' average price target is €69.71 (-2.72%). The median is €69.86 (-2.51%).

Buy	11
Hold	6
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Tempus AI posts strong Q3 results — stock rises, analysts raise price targets

Tempus AI reported strong third-quarter results; the stock rose about 8.7% on the Nasdaq. BTIG raised its price target to $100 with a "Buy" rating, Needham reiterated the buy recommendation with a $89 target, and Jefferies removed its sell rating and now rates the stock "Hold" at $70. The data business remains the strongest revenue driver, and the planned acquisition of Personalis could add further growth. » More on deraktionaer.de
Tempus AI beats expectations and raises full-year revenue guidance slightly

Tempus AI reported Q3 revenue up 23% to $411.5 million, beating analysts’ estimates. Adjusted EBITDA was $25.6 million and earnings per share were $0.07 instead of the expected loss of $0.07. The company raised the lower end of its full-year revenue guidance to $1.60 billion; adjusted EBITDA remains around $65 million. The stock rose just over 4% in premarket trading. » More on deraktionaer.de
Tempus AI jumps about 15% to a year high

The stock of Tempus AI climbed nearly 15% to $80.36, reaching a new year high. Market participants view this as a reaction to the company’s growth potential, the acquisition of Personalis, and comments by Eric Lefkofsky on AI in healthcare. Technically, the breakout above the August high on heavy volume delivered a clear buy signal, and analysts had already issued buy recommendations. Tempus AI benefits from its growing dataset for personalized medicine, which is expected to gain importance over the long term. » More on deraktionaer.de
Tempus AI jumps after Morgan Stanley flags $330M–$400M reimbursement upside

Tempus AI shares surged about 30% this week after Morgan Stanley highlighted reimbursement pricing that could add $330 million to $400 million in annual revenue from xT and xF diagnostics. CEO Eric Lefkofsky said the company should exceed its 25% multiyear growth target, citing roughly $200 million in Q2 data licensing bookings from AstraZeneca, GSK and Merck. Management raised FY guidance and reiterated a path to positive free cash flow, though the stock still trades below its 52-week high and carries high beta and ongoing GAAP losses. » More on finance.yahoo.com
Tempus AI rises sharply after remarks on AI benefits in healthcare

Tempus AI's stock climbed about ten percent on Tuesday after founder and CEO Eric Lefkofsky emphasized that healthcare is likely to benefit most from AI. Tempus combines diagnostics and data services and uses extensive datasets and large AI models to improve diagnostics and help pharma companies develop drugs. The company has a market capitalization of roughly $12 billion and is aiming to grow in precision oncology with the planned acquisition of Personalis; a break above the August high would open up further upside potential. » More on deraktionaer.de

Financials

In the last quarter, Tempus AI had revenue of €363.33m and net profit of -€13.11m

(EUR)	September 2026	YoY
Revenue	363.33m	27.58%
Gross profit	235.46m	31.62%
Net profit	-13.11m	80.76%
EBITDA	18.08m	154.71%

Fundamentals

Metric	Value
Market capitalization	€12.08bn
Number of shares	177.36m
52-week high/low	€79.79 - €36.51
Dividends	No
Beta	3.61
P/E ratio	-72.43
PEG ratio	13.22
P/B ratio	27.56
P/S ratio	8.94

Company profile

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.